Jasper Therapeutics executes 1-for-30 reverse stock split - Investing.com
Investing.com · Nov 4, 1:10 PM
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split - GlobeNewswire
GlobeNewswire · Nov 4, 1:00 PM
Market reactionShares rose 20% on Nov 6.
Jasper Therapeutics is a clinical-stage company developing immune-disease drugs, led by the complement inhibitor vensobafusp alfa (KP104) and the anti-KIT antibody briquilimab; none of its products is approved.
After acquiring Kira Pharmaceuticals in July, Jasper's lead program is vensobafusp alfa (KP104), a biologic that blocks two complement pathways. Its Phase 2 renal basket study in China has enrolled 18 IgA nephropathy patients, with initial data due by year-end. Jasper also plans an FDA end-of-Phase 2 meeting in PNH. Briquilimab is moving toward a pre-BLA meeting in SCID, with next steps due in early 2027. A $132 million private placement of preferred stock funds plans through 2H 2028, if stockholders approve its conversion.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Vensobafusp alfa shows early activity in IgA nephropathy
Does vensobafusp alfa show early efficacy and acceptable safety in IgAN at a practical subcutaneous schedule?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Jasper needs stockholders to approve its $132 million preferred conversion; IgAN data due
Merged Jasper/Kira bets a $132M raise on briquilimab's pre-BLA path in SCID, conditional on FDA accepting existing single-arm data as registrational
Post-merger anti-KIT antibody eyes pre-BLA filing in SCID, but Nasdaq delisting notice and going-concern doubt test whether $132M PIPE actually reaches it
Jasper-Kira merger resets the clock with $132M and a three-program pipeline, but briquilimab's pre-BLA path in SCID must validate before KP-104's Phase 3 case is built
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Kidney diseases, Blood disorders, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
9 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.